Tianshuang Wu

Publications by Year

Research Areas

Psoriasis: Treatment and Pathogenesis, Dermatology and Skin Diseases, Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical studies and practices, Advanced Causal Inference Techniques

Most-Cited Works

• → Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis(2021)459 cited
• → Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis(2020)203 cited
• → Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*(2020)196 cited
• → Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)(2023)47 cited
• → Identifying a set that contains the best dynamic treatment regimes(2015)41 cited
• → Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up(2023)40 cited
• → Power analysis in a SMART design: sample size estimation for determining the best embedded dynamic treatment regime(2018)34 cited
• → Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study(2022)25 cited
• → Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)(2023)20 cited
• → Efficacy of long‐term risankizumab treatment for moderate‐to‐severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial)(2024)15 cited